CITIUS ONCOLOGY INC (CTOR) Stock Fundamental Analysis

NASDAQ:CTOR • US17331Y1091

1.14 USD
-0.02 (-1.72%)
At close: Feb 23, 2026
1.11 USD
-0.03 (-2.63%)
After Hours: 2/23/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall CTOR gets a fundamental rating of 1 out of 10. We evaluated CTOR against 521 industry peers in the Biotechnology industry. Both the profitability and financial health of CTOR have multiple concerns. CTOR has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CTOR has reported negative net income.
  • CTOR had a negative operating cash flow in the past year.
CTOR Yearly Net Income VS EBIT VS OCF VS FCFCTOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • CTOR has a better Return On Assets (-24.53%) than 71.40% of its industry peers.
  • CTOR's Return On Equity of -55.19% is fine compared to the rest of the industry. CTOR outperforms 64.30% of its industry peers.
Industry RankSector Rank
ROA -24.53%
ROE -55.19%
ROIC N/A
ROA(3y)-24.09%
ROA(5y)N/A
ROE(3y)-34.59%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTOR Yearly ROA, ROE, ROICCTOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • CTOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTOR Yearly Profit, Operating, Gross MarginsCTOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, CTOR has more shares outstanding
  • The debt/assets ratio for CTOR is higher compared to a year ago.
CTOR Yearly Shares OutstandingCTOR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 20M 40M 60M 80M
CTOR Yearly Total Debt VS Total AssetsCTOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -0.82, we must say that CTOR is in the distress zone and has some risk of bankruptcy.
  • CTOR has a Altman-Z score of -0.82. This is comparable to the rest of the industry: CTOR outperforms 57.58% of its industry peers.
  • CTOR has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of CTOR (0.08) is worse than 61.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACCN/A
CTOR Yearly LT Debt VS Equity VS FCFCTOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 0.56 indicates that CTOR may have some problems paying its short term obligations.
  • CTOR has a worse Current ratio (0.56) than 89.64% of its industry peers.
  • A Quick Ratio of 0.11 indicates that CTOR may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.11, CTOR is doing worse than 93.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.11
CTOR Yearly Current Assets VS Current LiabilitesCTOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for CTOR have decreased by -8.75% in the last year.
EPS 1Y (TTM)-8.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CTOR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 89.47% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y115%
EPS Next 2Y89.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTOR Yearly Revenue VS EstimatesCTOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 20M 40M 60M 80M 100M
CTOR Yearly EPS VS EstimatesCTOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 0.2 -0.2 0.4 -0.4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • CTOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 2.11, the valuation of CTOR can be described as very cheap.
  • CTOR's Price/Forward Earnings ratio is rather cheap when compared to the industry. CTOR is cheaper than 99.42% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of CTOR to the average of the S&P500 Index (27.75), we can say CTOR is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 2.11
CTOR Price Earnings VS Forward Price EarningsCTOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTOR Per share dataCTOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CTOR's earnings are expected to grow with 89.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.47%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CTOR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CITIUS ONCOLOGY INC

NASDAQ:CTOR (2/23/2026, 8:00:01 PM)

After market: 1.11 -0.03 (-2.63%)

1.14

-0.02 (-1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13
Earnings (Next)05-12
Inst Owners10.24%
Inst Owner Change-18.17%
Ins Owners2.94%
Ins Owner Change8.37%
Market Cap100.64M
Revenue(TTM)N/A
Net Income(TTM)-24.76M
Analysts82.86
Price Target6.12 (436.84%)
Short Float %6.25%
Short Ratio3.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.35%
Min EPS beat(2)47.71%
Max EPS beat(2)50.98%
EPS beat(4)2
Avg EPS beat(4)7.95%
Min EPS beat(4)-47.06%
Max EPS beat(4)50.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.11
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.24
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.54
Fwd EY47.42%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0
BVpS0.51
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.53%
ROE -55.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.09%
ROA(5y)N/A
ROE(3y)-34.59%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.11
Altman-Z -0.82
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y115%
EPS Next 2Y89.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-813.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-813.37%
OCF growth 3YN/A
OCF growth 5YN/A

CITIUS ONCOLOGY INC / CTOR FAQ

What is the ChartMill fundamental rating of CITIUS ONCOLOGY INC (CTOR) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CTOR.


What is the valuation status of CITIUS ONCOLOGY INC (CTOR) stock?

ChartMill assigns a valuation rating of 4 / 10 to CITIUS ONCOLOGY INC (CTOR). This can be considered as Fairly Valued.


How profitable is CITIUS ONCOLOGY INC (CTOR) stock?

CITIUS ONCOLOGY INC (CTOR) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CTOR stock?

The Earnings per Share (EPS) of CITIUS ONCOLOGY INC (CTOR) is expected to grow by 115% in the next year.